The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

May 7, 2019 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Certolizumab pegol (Cimzia) is the first Fc-free, PEGylated anti-tumor necrosis factor therapy for adults with moderate to severe plaque psoriasis. The treatment has recently been approved for this patient population in Canada. Additionally, the U.K. has issued its final guidance for the clinical use of certolizumab pegol.

You Might Also Like
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
Also By This Author
  • Clinical Trials: Zilretta Promising for Knee OA Pain & Golimumab Completes Phase 3 Trial

Health Canada Approves Certolizumab Pegol
In late March, Health Canada approved certolizumab pegol for treating adults with moderate to severe plaque psoriasis.1 Additionally, Health Canada has approved updated product labeling for pregnant and breastfeeding patients based on two pivotal pharmacokinetic studies. This update signifies major progress for Canadian women of all ages living with plaque psoriasis and other autoimmune diseases.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

This approval was based on data from three clinical trials: CIMPASI-1, CIMPASI-2 and CIMPACT, which included 1,020 adult patients. Nearly one third of enrolled patients had prior biologic exposure. Each study assessed the percentage of patients who achieved at least 75–90% or greater disease improvement from baseline, as measured by the Psoriasis Area and Severity Index (PASI75 and PASI90) compared with placebo. The PASI75 response was a primary endpoint.

The CIMPASI-1 and CIMPASI-2 trials were 16 weeks, and the CIMPACT trial was 12 weeks. At Week 16, all three trials assessed the percentage of patients who achieved at least a two-point improvement on a five-point Physician’s Global Assessment (PGA) scale to a final score representing clear or almost clear skin compared with placebo.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

At Week 12, certolizumab pegol demonstrated statistically significant improvements in the percentage of patients achieving 75% or greater disease improvement from baseline (PASI75) compared with placebo-treated patients. In all three trials, certolizumab pegol-treated patients demonstrated statistically significant improvements for all primary and co-primary endpoints compared with placebo-treated patients at all tested doses. The clinical benefit of treatment was maintained through Week 48.

According to the updated label, the recommended dose of certolizumab pegol for adults with moderate to severe plaque psoriasis, including women who are pregnant and breastfeeding, is 400 mg every other week, given as two subcutaneous injections of 200 mg each. A dose of 400 mg initially (Week 0) and at Weeks 2 and 4, followed by 200 mg every two weeks, may be also considered.

NICE Guidance on Certolizumab Pegol
In April, the National Institute for Health and Care Excellence (NICE) in the U.K. published its final guidance for use of certolizumab pegol for treating adults with severe plaque psoriasis for whom other systemic therapies have not worked. The guidance notes that women can use this treatment before and during pregnancy if needed, as well as while breastfeeding.2

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: breastfeeding, Canada, Certolizumab Pegol, NICE, plaque psoriasis, pregnant women, U.K.

You Might Also Like:
  • Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
  • Certolizumab Pegol Promising for Plaque Psoriasis in Phase 3 Trial
  • Ixekizumab Promising for AS; Plus Certolizumab Pegol Studied for Psoriasis
  • EU Approves Certolizumab Pegol for Pregnant & Nursing Patients

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.